Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.31 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5228979 | 0.71 | LTA4H (0.38) | KCNH2NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL7205715 | 0.71 | KCNH2 (0.35) | KCNH2RAB9ASMN1; SMN2MAPTCYSLTR2 | |
| SCHEMBL864159 | 0.69 | KDM4E (0.58) | KCNH2SMN1; SMN2 | |
| SCHEMBL7207747 | 0.69 | KCNH2 (0.36) | KCNH2SMN1; SMN2MAPTCYSLTR2CYSLTR1 | |
| SCHEMBL3144663 | 0.69 | — | — | |
| SCHEMBL3098479 | 0.68 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL5757765 | 0.68 | ACACB (0.41) | NPC1RAB9ASMN1; SMN2CYSLTR2CYSLTR1 | |
| SCHEMBL865233 | 0.68 | SYK (0.37) | KCNH2SMN1; SMN2CYSLTR2CYSLTR1 | |
| SCHEMBL5756963 | 0.68 | SYK (0.37) | KCNH2SMN1; SMN2CYSLTR2CYSLTR1 | |
| SCHEMBL863712 | 0.67 | KCNH2 (0.50) | KCNH2CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608104-B2 | Antiarthritic agents; anticancer agents | PFIZER INC | 2003-08-19 | — | — | US | claimed |
| US-20020019534-A1 | Gem substituted hydroxamic acids | PFIZER INC. | 2002-02-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019534-A1 | Gem substituted hydroxamic acids | MMP14, TOP2A, ADAMTS1 | KCNH2 3773/4885NPC1 2604/4885RAB9A 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.